1. Home
  2. ASM vs AVLN Comparison

ASM vs AVLN Comparison

Compare ASM & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avino Silver & Gold Mines Ltd. (Canada)

ASM

Avino Silver & Gold Mines Ltd. (Canada)

HOLD

Current Price

$4.71

Market Cap

1.3B

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

SELL

Current Price

$26.91

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ASM
AVLN
Founded
1968
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2005
2026

Fundamental Metrics

Financial Performance
Metric
ASM
AVLN
Price
$4.71
$26.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$10.51
★ $61.80
AVG Volume (30 Days)
★ 2.9M
378.3K
Earning Date
11-04-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$58.01
N/A
Revenue Next Year
$43.25
N/A
P/E Ratio
$67.93
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.05
$22.24
52 Week High
$11.99
$40.17

Technical Indicators

Market Signals
Indicator
ASM
AVLN
Relative Strength Index (RSI) 29.44 50.30
Support Level N/A $24.90
Resistance Level $6.52 $28.52
Average True Range (ATR) 0.22 1.81
MACD -0.03 0.43
Stochastic Oscillator 6.72 72.83

Price Performance

Historical Comparison
ASM
AVLN

About ASM Avino Silver & Gold Mines Ltd. (Canada)

Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: